Welcome back. The previous lesson explained why removing a keloid does not guarantee it will stay away: excision creates a new wound, and additional treatment aims to reduce regrowth. This final lesson is about judging the numbers used to describe those treatments. A reported “success rate” may mean less itching, a flatter scar, or no visible regrowth during a particular follow-up period. Those are useful outcomes, but they are not the same as permanent removal.
What did the study count as success?
Treatment can help in stages. Itching or pain may ease before a keloid visibly flattens. A scar can also become flatter without disappearing. That distinction matters when a headline calls a treatment “effective.”
This short clinician video makes the difference between symptom relief and visible flattening concrete. It also illustrates why a person might value improvement even when the treated skin does not return to its original appearance.
Tips, tricks, and pearls for keloid scar steroid injections
Watch “Tips, tricks, and pearls for keloid scar steroid injections” from MDedge for a clinician’s description of treatment goals, rather than for instructions on performing injections.
Watch different timelines for symptom relief and flattening. Then watch the outcome discussion, focusing on the trade-off between a flatter, more comfortable scar and possible changes in skin color or thickness. This is one clinician’s account of patient preferences, not a measure of how everyone values those outcomes.
A research paper must turn “effective” into a rule it can count. In the following systematic review, an efficacy event includes substantial improvement in scar size, height, volume, flattening, or a scar-scale score. Read its definition before interpreting any treatment ranking.
Read the systematic review’s “Eligibility Criteria” subsection to see how it defines efficacy. The key point is what qualifies a treated scar to be counted as improved.
In “Eligibility Criteria,” find the paragraph beginning “The inclusion criteria were as follows.” Read its efficacy definition from the counting rule. Notice that the rule includes substantial improvement; it does not require the scar to vanish permanently.
Suppose a study treats 100 keloids and reports 75% efficacy at three months, using a threshold of at least 50% improvement. Its result means that 75 met that study’s improvement rule at that assessment. It does not mean 75 people have scar-free skin, that their symptoms all resolved, or that none of those scars will grow again.
“Recurrence” needs its own rule. A study might count new tissue growing along a surgical scar, any elevation at the treated site, growth beyond the incision, or the return of symptoms alongside visible changes. These definitions identify different sets of events. Likewise, a 20% recurrence rate is incomplete until the report states 20% of whom: all treated participants, only scars that initially cleared, or another group. Efficacy and recurrence rates cannot simply be subtracted from 100% to calculate a permanent cure rate.
How a study recognizes regrowth
The review below examines a particular problem in studies of excision followed by radiotherapy: researchers do not consistently define recurrence or follow scars for the same length of time. Its table is useful because it places different definitions side by side.
Assessing keloid recurrence following surgical excision and radiation
Read this review for its comparison of recurrence definitions and follow-up periods, not to select a radiation regimen.
In the introductory discussion immediately before the “Review” heading, read the comparison problem. In “Review,” find the paragraph beginning “In several trials with electron beam radiation therapy.” Read the examples, then scan Table 1, “Keloid recurrence definition assessments,” for how much the definitions vary. After Table 1, find the paragraph beginning “Three studies used the Kyoto Scar Scale” and read the scale descriptions. Focus on the distinction between visible signs and reported symptoms.
A scar scale can capture more than a yes-or-no judgment about recurrence. The JSW Scar Scale pictured below, for example, has a classification side that incorporates risk factors and existing scar features, and a separate evaluation side that scores findings during follow-up.

This separation prevents a common reading error. A lower follow-up score can show meaningful relief even if a visible scar remains. Conversely, a study defining recurrence as any elevation could count a small raised area that another study, using growth beyond the incision as its rule, would not count. Neither study’s number makes sense without its definition.
Why time and body site change the interpretation
Follow-up duration is part of the result. A photograph showing a flat surgical site shortly after excision demonstrates an early appearance, not long-term control. Regrowth may be recorded later. Studies with follow-up ranging from months to years therefore have different opportunities to detect it. When you read a rate, look for when the last assessment occurred and whether participants were still being followed then.
The body site and scar history matter too. Results from primary earlobe keloids after piercing should not automatically be applied to a recurrent keloid on the central chest. The next passage describes that contrast without claiming every keloid at either site behaves alike.
Return to the systematic review for its discussion of why treatment results must be applied to the type and site of keloid actually being treated.
In “Discussion,” locate the paragraph beginning “Although our network meta-analysis identifies highly effective combination therapies for keloid management.” Read the site comparison. Pay particular attention to its contrast between a primary earlobe keloid and a recurrent presternal keloid.
Treatment details complete the picture. “Surgery” can mean excision alone or excision followed by injections or radiotherapy. Those are not interchangeable plans. Even within a named combination, schedules and follow-up care may differ. The radiation review reports recurrence estimates for excision plus radiation that are lower than figures it cites for excision alone, but those figures should not be treated as a personalized head-to-head prediction: the underlying studies differ in methods, definitions, and follow-up.
Consider two hypothetical claims:
Study A: “75% treatment success.” Keloids at several body sites received injections. Success meant at least 50% improvement at three months.
Study B: “20% recurrence.” Earlobe keloids were excised and received additional treatment. Recurrence meant new raised growth during two years of follow-up.
Study A offers evidence about early improvement under an injection plan. Study B offers evidence about observed regrowth after a different treatment at a specified site. The numbers do not establish that one plan is better, and neither promises permanent removal. To compare them responsibly, you would need studies with comparable keloids, treatment combinations, outcome definitions, and follow-up.
A reliable way to read the next claim
When you encounter a treatment rate, attach five details to the number: the treatment combination, the body site and scar history, who was counted, the definition of the outcome, and the length of follow-up. If a report omits them, its percentage is too thin to support a personal prediction.
The central takeaway is that relief, flattening, and freedom from observed recurrence are distinct achievements. Each may matter, but “effective” does not automatically mean “gone forever,” and “no recurrence during follow-up” is not a lifetime guarantee. This completes the course: you can now connect how keloids form and differ from other bumps with prevention limits, reasons to seek assessment, treatment trade-offs, and the careful interpretation of reported results.